![GI cancers – rapid oral abstracs in ASCOBT 24 summarized by Erman Akkus](https://oncodaily.com/pub/uploads/2024/08/5dijQf_m_400x400-1-e1723477511127.png)
Photo from Erman Akkus/X
Aug 12, 2024, 21:46
GI cancers – rapid oral abstracs in ASCOBT 24 summarized by Erman Akkus
Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, shared on X:
“GI cancers- rapid oral abstracts in ASCOBT (Breakthrough) 24.
- 221- The impact of HRD mutation on survival in patients with KRAS-mutated advanced pancreatic cancer.
HRD+ve pts had better time-to-treatment failure when treated with mFOLFIRINOX, but not with gemcitabine-nab-paclitaxel.
- 196- Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial).
Bite-on-bite biopsies and EUS-FNA for lymph nodes are accurate, ctDNA may help.
- 50- Outcomes in Child-Pugh (CP) B liver function treated with atezolizumab plus bevacizumab (A+B) for hepatocellular carcinoma (HCC).
No additional safety risks, may still benefit.
- 34- Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in advanced HCC with macrovascular invasion: Departure.
The combination is safe.”
Source: Erman Akkus/X
Other posts featuring Erman Akkus on OncoDaily.